All results
21 results for observational study hepatitis c virus pregnancy
-
ITN095AI DESIGNATE
This is a multicenter, Phase Ib, open-label, siplizumab dose-finding study in individuals aged 8-45 years with a Type 1 diabetes mellitus (T1DM) diagnosis.…
- Ages
- 8 Years - 45 Years
- Sexes
- All
-
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cance
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment…
- Ages
- 18 Years - N/A
- Sexes
- All
-
Intravesical BCG vs GEMDOCE in NMIBC (BRIDGE)
The study hypothesis is that BCG naïve non-muscle invasive bladder cancer (NMIBC) patients treated with intravesical Gemcitabine + Docetaxel (GEMDOCE) will…
- Ages
- 18 Years - N/A
- Sexes
- All
-
NIH AIM 2 - Low Dose Pioglitazone in NASH
To determine the safety and efficacy of low-dose pioglitazone (15 mg per day) on liver histology in in patients with T2DM with biopsy-proven nonalcoholic…
- Ages
- 21 Years - 75 Years
- Sexes
- All
-
GCAptAIN
This is a phase III study of efficacy and safety of secukinumab versus placebo, in combination with glucocorticoid taper regimen, in patients with giant cell…
- Ages
- 50 Years - N/A
- Sexes
- All
-
Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
This phase II ComboMATCH treatment trial evaluates the effectiveness of palbociclib and binimetinib in treating patients with RAS-mutated cancers. Palbociclib…
- Ages
- 18 Years - N/A
- Sexes
- All
-
Immunotherapy for Patients With Advanced Kidney Cancer, The PDIGREE Study
This phase III trial compares the usual treatment (treatment with ipilimumab and nivolumab followed by nivolumab alone) to treatment with ipilimumab and…
- Ages
- 18 Years - N/A
- Sexes
- All
-
Pembro With Investigational Agents or Pembro Alone in First Line (1L) Advanced Melanoma
Substudy 02B is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella…
- Ages
- 18 Years - 120 Years
- Sexes
- All
-
SANOFI 16035 PERSEUS
### Primary Objective: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in primary progressive multiple sclerosis…
- Ages
- 18 Years - 55 Years
- Sexes
- All
-
XTMab
A phase 1b/2 study of XTMAB-16 in patients with pulmonary sarcoidosis ### Inclusion Criteria: 1. Participant between 18 to 80 years (inclusive) of age. 2.…
- Ages
- 18 Years - 80 Years
- Sexes
- All